Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of ulcerative colitis~Exclusion Criteria:~* a history of allergy or hypersensitivity to salicylates or aminosalicylates;~* a history of extensive small bowel resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
- 2 (Type: EXPERIMENTAL): mesalamine 4.8 g/day (800 mg tablet) for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).